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ABSTRACT 
Caveolin-1 (CAV1) is the main structural component of Caveolae which are plasma membrane 
invaginations that participate in vesicular trafficking and signal transduction events. Although 
evidence has recently accumulated describing the function of CAV1 in several cancer types, its 
role in melanoma tumor formation and progression remains poorly explored. Here, by employing 
B16F10 melanoma cells as an experimental system, we directly explore the function of CAV1 in 
melanoma tumor growth and metastasis. We first show that CAV1 expression promotes 
proliferation, while it suppresses migration and invasion of B16F10 cells in vitro. When 
orthotopically implanted in the skin of mice, B16F10 cells expressing CAV1 form tumors that are 
similar in size to their control counterparts. An experimental metastasis assay demonstrates that 
CAV1 expression suppresses the ability of B16F10 cells to form lung metastases in C57Bl/6 
syngeneic mice. Additionally, CAV1 protein and mRNA levels are found to be significantly 
reduced in human metastatic melanoma cell lines and human tissue from metastatic lesions. 
Finally, we demonstrate that following integrin activation, B16F10 cells expressing CAV1 
display reduced expression levels and activity of FAK and Src proteins. Furthermore, CAV1 
expression markedly reduces the expression of integrin β3 in B16F10 melanoma cells. In 
summary, our findings provide experimental evidence that CAV1 may function as an 
antimetastatic gene in malignant melanoma. 
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INTRODUCTION 
 Malignant Melanoma remains among the most life threatening of all cancers, and its 
incidence has been rising dramatically in the last decades. Despite great progress in understanding 
the genetics and biochemistry of malignant melanoma, patients with metastatic disease have very 
few treatment options available. The establishment of metastases in distant organs of the body is a 
stepwise process that begins with the invasion of the dermis surrounding the primary tumor and 
ends with the colonization of ectopic sites (1). Each of the steps of the metastatic cascade is rate 
limiting. Thus, identifying novel mechanisms and factors regulating melanoma progression may 
be critical for the development of new therapeutics in this type of cancer.  
 Initially identified by electron microscopy (2), Caveolae are 50-100nm large plasma 
membrane invaginations morphologically distinct from the classical clathrin coated vesicles (3). 
Three different Caveolin genes (CAV1, 2, and 3) encode for the structural components of these 
organelles (4) (5). CAV1 is the best studied of the three Caveolins, and it is considered a 
multifunctional scaffold protein able to bind and  regulate the activity of numerous signaling 
molecules within Caveolae (6). Due to the multitude of interacting proteins described, CAV1 has 
been implicated in the modulation of several cancer-associated phenotypes including cell 
proliferation, death, and transformation (4). Aside from data derived from cell culture 
experiments, there are several lines of clinical and genetic evidence implicating CAV1 as a tumor 
suppressor in vivo.  First, CAV1 has been found to be down-regulated and/or mutated in a number 
of human tumors including mammary adenocarcinomas and squamous cell carcinomas (7) (8).  
Second, the generation of CAV1 KO mice has allowed for the validation of the hypothesis that 
CAV1 may behave as a tumor suppressor. Although CAV1 KO mice do not develop spontaneous 
tumors, they are more susceptible to carcinogen (DMBA)-and oncogene-induced cancer in skin 
and mammary tissue, respectively (9) (10). However, the idea that CAV1 may be a “general” 
tumor suppressor has been recently challenged by reports showing that CAV1 expression is 
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cancer type and/or stage dependent (11). CAV1 is upregulated in bladder, esophagus, thyroid 
(papillary subtype), and prostate carcinomas, and this upregulation seems to be associated with 
multidrug resistance and/or metastasis (12, 13).  
 The role of CAV1 in malignant melanoma, instead, remains poorly understood. Several 
groups have reported conflicting results for the role of CAV1 in melanoma transformation, 
migration, and invasion (14, 15). Furthermore, the role of CAV1 in melanoma tumor formation 
and metastasis remains to be determined. Here, to gain better insight into the function of CAV1 in 
melanoma progression, we employed B16F10 melanoma cells as an experimental system to 
directly explore the function of CAV1 in melanoma tumor growth and metastasis. 
 In the current study, we show that CAV1 expression inhibits the motility of B16F10 
melanoma cells in vitro and their ability to form lung metastases in vivo. These results were 
consistent with reduced CAV1 expression in a panel of human metastatic melanoma cell lines and 
metastatic lesions of human patients. Finally, recombinant CAV1 expression in B16F10 cells was 
sufficient to suppress the expression and the activity of Src and FAK proteins following integrin 
engagement. In summary, these data underscore the importance of CAV1 as a new antimetastatic 
gene in malignant melanoma.  
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MATERIALS AND METHODS 
Materials. Antibodies and their sources were as follows:  p-FAK(Y397) and p-Src(Y418) were 
from Invitrogen. CyclinD1, CyclinA , Bcl-2 , Integrin α5, Integrin β1, and CAV1(N-20) were 
from Santa Cruz Biotechnology. FAK, and CAV1 were from BD. Src, Integrin α6, Integrin αV 
(Ab1930) were from Millipore.  Integrin β3, AKT, and p-AKT(S473) were from Cell Signaling. 
β-Tubulin was from Sigma, S-100b was from Affinity BioReagents, and GAPDH was from 
Fitzgerald. 
Mice Experiments.  Orthotopic Injections were performed by intradermally injecting 106 
B16F10 cells, whereas intravenous (IV) injections of 105 cells were used to assay for 
Experimental Metastasis in 3-4-mo-old C57Bl6/J female mice (16) (17). All in vivo studies were 
approved by the IACUC of Thomas Jefferson University. Detailed descriptions are available in 
Supplementary Methods.  
Cell Lines. B16F0, B16F10, A-375, WM-115, SK-MEL-28, SK-MEL-5, WM-266-4, WM-35, 
and Normal Human Epidermal Melanocytes (NHEM) were cultured according to manufacturer’s 
instructions (ATCC, Coriell, and Science Cell Research Laboratories). ATCC and Coriell 
routinely perform DNA profiling to authenticate their cell lines. For all the in vitro and in vivo 
experiments only early passages of these cells (passages 5-6) were used.   
Retrovirus Infection. pBabe-Puro and pBabe-CAV1-Puro retrovectors were used to stably 
transduce melanoma cells (18). 
Western Blots. Melanoma cells were sonicated and lysed in a modified RIPA buffer and 
processed for Western Blot analysis as we previously described (19). 
Protein Fractionation and Triton X-100 Solubility Assay. Triton X-100 solubility assay was 
performed as previously described (18). Cytoplasm and membrane proteins were extracted using 
a commercially available kit (Pierce Biotechnology).  
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Growth Curves, Cell Cycle Analysis, and Proliferation assay. Growth curves were generated 
by seeding 2 x 103 cells/cm2 in triplicate. 1, 2, 3, and 4 days after seeding cells were dissociated 
and cell number counted with hemacytometer. Cell cycle analysis was conducted by Flow 
Cytometry Analysis of Propidium Iodide stained cells (20). DNA synthesis in cells was directly 
analyzed by [3H]-Thymidine incorporation assay (21). Cell proliferation was also estimated by 
immunostaining cells with the proliferation marker Ki67 (Abcam). 
Immunofluorescence. Cells were grown on glass coverslips and double immunostained for 
CAV1 and CAV2 as previously described (18). Slides were mounted with the Pro-Long Gold 
antifade reagent (Molecular Probes) and imaged by confocal microscopy (LSM 510 META 
Confocal; Zeiss).  
Tissue Scan Melanoma Panel and qRT-PCR. As previously described (22), a commercial 
panel of human cDNAs, obtained from normal human skin tissue and from human melanoma 
metastatic lesions (Stages III & IV), was purchased from OriGene Technologies (MERT501). 
qRT-PCR was performed using ready-to-use CAV1 and RPL13a primers/SYBR master mixes 
(SA-Biosciences). Quantitative expression data were acquired using ABI-Prism 7900HT 
Sequence Detection System (Applied Biosystems) and results were analyzed by the ∆∆Ct method 
(23).  
Immunohistochemistry (IHC) of Tissue Sections. A tissue microarray (TMA) of paraffin 
embedded human melanoma tissue samples were purchased from US Biomax (Mel207; 69 
cases/207 cores) and was stained for CAV1(N-20) using standard IHC techniques (9). An expert 
dermatopathologist carefully analyzed and blindly scored the tissues cores for semiquantitative 
analysis of immunoreactivity.  Detailed descriptions are available in Supplementary Methods. 
Migration and Invasion assays.  5x104 cells suspended in 0.5 ml of SFM containing 0.1% BSA 
(Sigma) were added to the wells of 8µm pore polycarbonate membrane, either coated with (for 
chemoinvasion assays) or without (for chemotaxis assays) Matrigel (Transwells; BD 
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Biosciences). Serum-free NIH3T3 conditioned medium (48h) was used as a chemoattractant. 
After 6h, the cells that had migrated were stained and counted as previously described by others 
(17).  For studies using Src and FAK inhibitors, SKI-606 (Selleck), PF-573,228 (Tocris 
Bioscience), or DMSO were placed in both the upper and lower chambers.    
Adhesion/Suspension Assays. Integrin engagement was performed as described before (24). 
After being maintained in serum-free medium (SFM) containing 0.1% BSA for 18h, cells were 
dissociated, suspended in medium containing 0.1% BSA, and replated on Fibronectin (FN)-
coated plates (BD) for 1h at 37 oC. Cells were either lysed immediately or lysed following the 
addition of complete medium (10% FBS) for 10 minutes. Alternatively, following 18h serum 
starvation, cells were dissociated and left in suspension for 1h, and then processed for Western 
Blot analysis. 
Statistical Analysis. Results are represented as the means ± SEM. Statistical analyses were 
performed using the Prism 4.0 Program (GraphPad Software, Inc San Diego, CA).  
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RESULTS 
CAV1 protein is correctly targeted to the plasma membrane of B16F10 melanoma cells. Lack 
of CAV1 expression has been described in several metastatic melanoma cell lines including 
B16F10 cells (25) (26) (15). Western blot analysis showed that a high expression level of CAV1 
was achieved in B16F10 cells transduced with pBabeCAV1. CAV2 expression was not affected 
by CAV1 expression in B16F10 melanoma cells. Identical results were obtained with the low 
metastatic B16F0 melanoma cell line (Fig. 1A). To determine the subcellular localization of 
CAV1 and CAV2, we next performed confocal microscopy on pBabe and pBabeCAV1 
transduced cells. Serial optical images (z sections) of pBabe and pBabeCAV1 B16F10 melanoma 
cells double immunostained with CAV1 and CAV2 antibodies showed that recombinant CAV1 is 
correctly targeted to the plasma membrane of B16F10 cells. As expected, CAV2 colocalized with 
CAV1 at the plasma membrane, despite the fact that a large portion of CAV2 also colocalized 
intracellularly (perinuclear) with CAV1 (Fig 1B). These results were further confirmed by the 
observation that the CAV1/CAV2 complex was enriched in the membrane fraction and in the 
Triton X-100 insoluble fraction of B16F10 cells expressing CAV1 (Fig. 1C, 1D). Thus, these 
results provide evidence that the CAV1/CAV2 complex is correctly targeted to the plasma 
membrane of B16F10 cells following the re-expression of CAV1 by retroviral strategy.  
 
CAV1 expression promotes proliferation of B16F10 melanoma cells in vitro. Given the role of 
CAV1 in regulating proliferation and cell cycle progression (27), we next performed a 
proliferation assay and cell cycle analysis. Interestingly, growth curves (in 5% and 10% FBS) and 
[3H]-Thymidine incorporation assay showed enhanced cell growth and increased DNA synthesis 
in B16F10pBabeCAV1 cells (140 ±13 vs. 98 ±7 cpm/mg in pBabeB16F10) (Fig. 2A and 2B). 
FACS analysis of asynchronously growing cells showed a significantly increased percentage of 
B16F10pBabeCAV1 cells in the S and G2M phases of the cell cycle (Fig. 2C, Supplemental 
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Table 1). CAV1 expression in B16F10 cells was also associated with increased CyclinD1 and 
CyclinA expression and increased Ki67 positivity as determined by Western Blot and 
immunoflurescence analysis (Fig. 2D). These results demonstrate a pro-proliferative role for 
CAV1 in the B16F10 melanoma cell line.  
 
CAV1 expression decreases migration and invasion of B16F10 melanoma cells in vitro. 
Migration and invasion through a basement membrane are hallmarks of malignancy. To 
determine whether CAV1 expression affects these properties, pBabe and pBabeCAV1 B16F10 
cells were subjected to migration (chemotaxis) and chemoinvasion assays. Specifically, we 
observed a roughly 2-fold reduction in the capacity of pBabeCAV1 B16F10 cells to migrate 
through the polycarbonate membrane of transwell chambers when NIH3T3 serum-free 
conditioned medium was used as a chemoattractant. Moreover, when cells were subjected to 
chemoinvasion assays, we observed a reduced capacity (roughly 2-fold reduction) of 
pBabeCAV1 B16F10 cells to invade through Matrigel coated transwell chambers when NIH3T3 
conditioned medium was used as a chemoattractant (Fig. 3). These results, along with the results 
from our proliferation assays, suggest that CAV1 inhibits migration and invasion, while 
maintaining a positive effect on cell cycle progression in B16F10 melanoma cells.  
 
CAV1 expression dramatically reduces the metastatic potential of B16F10 cells in vivo without 
affecting primary tumor growth. To determine the effect of CAV1 expression on B16F10 tumor 
growth in vivo, 106 pBabe and pBabeCAV1 B16F10 melanoma cells were orthotopically 
(intradermally) implanted in the skin of 3-4-month-old C57Bl/6 female mice. 18 days after 
injections, the determination of tumor size and weight revealed that tumor growth was not 
significantly different between B16F10pBabe and B16F10pBabeCAV1 (Fig. 4A). Additionally, 
lungs dissected from both groups of mice did not show any spontaneous metastasis formation. To 
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assess whether CAV1 expression was able to affect the metastatic potential of B16F10 melanoma 
cells, 105 B16F10pBabe and B16F10pBabeCAV1 cells were IV injected in 3-4 month old 
C57Bl/6 female mice (experimental lung metastasis). After 18 days, examination of lungs 
revealed that the incidence of metastasis was significantly reduced in the B16F10pBabeCAV1 
injected mice (42%) compared to the B16F10pBabe injected animals (94%) (Fig. 4B; 
Supplementary Table 2). Strikingly, the B16F10pBabeCAV1 injected mice that showed 
metastasis formation displayed a significant reduction (roughly 3.5 fold) in the number of visible 
metastases per lung compared to the B16F10pBabe injected mice (Fig. 4C, D). Consistent with 
the ability of CAV1 to reduce the motility of B16F10 cells in vitro, these results demonstrate that 
CAV1 expression suppresses the metastatic potential of B16F10 cells without affecting primary 
tumor growth in vivo. 
 
CAV1 expression is reduced in human metastatic melanoma cell lines and human tissue 
samples derived from metastatic lesions. Because CAV1 expression had no effect on the growth 
of B16F10 derived tumors, we next wanted to determine CAV1 expression levels in a panel of 
primary and metastatic melanoma derived cell lines. Immunoblot analysis revealed that CAV1 
expression was significantly reduced in metastatic melanoma cell lines (SK-MEL-28, A-375, SK-
MEL-5, WM-266-4) compared to primary melanoma derived cell lines (WM35, WM115). 
Interestingly, primary human melanocytes displayed complete absence of CAV1 expression (Fig. 
5A). To validate the significance of the expression pattern observed in melanoma cell lines, we 
next determined CAV1 expression by IHC in normal skin, primary melanoma samples, and 
metastatic lesions from 69 melanoma patients (207 tissue cores). CAV1 immunoreactivity scores 
revealed that ~90% of the metastatic lesions showed absence (scored as 0) or weak (scored as 1) 
CAV1 staining. In contrast, we observed that only 30% of the primary melanoma samples 
showed absent or weak CAV1 staining (Fig. 5B). In cores that stained positive, CAV1 was 
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observed to localize in the cytoplasm and at the plasma membrane of melanoma cells (Fig. 5C, 
center). In the skin, instead, CAV1 immunostaining was observed in the keratinocytes of the 
basal cell layer as we have previously described (Fig. 5C, left) (9). To further analyze the extent 
of CAV1 alterations in melanoma progression, we determined CAV1 expression by qRT-PCR on 
cDNA obtained from Stage III (n=20) and Stage IV (n=19) metastatic lesions. Analysis of CAV1 
mRNA levels revealed that CAV1 expression was significantly reduced in Stage IV metastases 
compared to Stage III metastases (Fig. 5D, left). In addition, when CAV1 mRNA levels for both 
Stages III and IV metastatic lesions were combined, they were significantly reduced (~2 fold 
reduction) when compared to CAV1 mRNA levels in normal skin (Fig. 5D, right). Taken 
together, these findings suggest that CAV1 loss is a late event in melanoma progression, and they 
imply that CAV1 may be involved in regulating mechanisms affecting the metastatic process.  
 
CAV1 expression suppresses the Integrin/Src/FAK pathway following integrin engagement in 
B16F10 melanoma cells.  A large body of experimental evidence has described Integrin-ECM 
interactions as being critical to acquire metastatic competence in melanoma (28) (29). CAV1 has 
often been described as an important component necessary to regulate the Integrin/Src/FAK 
pathway in both normal and tumor cell lines (30, 31) (26). In order to determine whether the 
Integrin/Src/FAK pathway may be altered by CAV1 expression, we plated B16F10pBabe and 
B16F10pBabeCAV1 cells on FN coated plates and then cultured them in the presence or absence 
of serum. Remarkably, in the absence of serum, B16F10pBabeCAV1 showed a significant 
reduction in FAK(Y397) and Src(Y418) activation when compared to B16F10pBabe cells due at 
least in part to a reduction in total levels of FAK and Src proteins (Fig. 6A, left). In the presence 
of serum, B16F10pBabeCAV1 corroborated the reduced FAK and Src activity seen in serum-free 
conditions. These results, however, were not associated with reduced expression of FAK/Src 
proteins, suggesting that CAV1 interferes directly with the integrin signaling (Fig. 6A, right). We 
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next determined the expression of several integrin subunits that have been associated with 
FAK/Src signaling and melanoma metastasis (32) (33). Interestingly, in both presence and 
absence of serum, B16F10pBabeCAV1 plated on FN displayed a dramatic reduction in the 
expression of integrin β3. Expression of integrin α5 was also reduced in B16F10pBabeCAV1 but 
only in presence of serum. No changes were observed in the expression of β1, αV, and α6 
integrins (Fig. 6A). Expression and activity of Src and FAK proteins were unchanged in cells 
maintained in suspension (with and without serum), demonstrating that CAV1 inhibits the 
Integrin/Src/Fak pathway in an adhesion dependent manner (Fig. 6B). Given the role of CAV1 in 
regulating cell proliferation (27, 34), we next wanted to determine whether pathways involved in 
melanoma cells proliferation were altered by CAV1 expression after integrin activation. 
Immunoblot analysis revealed reduced expression of CyclinD1 and Bcl-2 proteins in 
B16F10pBabeCAV1 cells plated on FN in the absence of serum. Following addition of serum, 
B16F10pBabeCAV1 cells displayed increased levels of Bcl-2, CyclinD1, and total Akt proteins 
(Fig. 6C, bottom). These results were consistent with the proliferation rates of B16F10pBabe and 
B16F10pBabeCAV1 grown on FN for 12h (Fig. 6C, top). Interestingly, Bcl-2 expression was 
also found increased in human metastatic melanoma cell lines compared to primary cell lines 
indicating an inverse correlation with CAV1 expression (Fig. S1).  The importance of the 
Integrin/Src/Fak pathway in regulating motility was further proved by the ability of Src 
(Bosutinib) and FAK (PF-573,228) inhibitors to significantly reduce the migration and invasion 
of B16F10 cells (Fig. S2).  Taken together, these findings suggest that in absence of a 
proliferative stimulus (serum), CAV1 has a negative effect on the proliferative pathways of 
B16F10 cells following Integrin/Src/FAK pathway activation. In contrast, in the presence of a 
proliferative stimulus, CAV1 expression activates pathways that promote proliferation after 
integrin activation. Nevertheless, our results demonstrate that CAV1’s ability to suppress the 
Integrin/Src/Fak pathway is serum independent.  
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DISCUSSION    
In the present study, we have established the function of CAV1 in melanoma tumor cell growth 
and metastasis using both the murine B16F10 melanoma cell line and human melanoma tissue 
samples.  For the first time, we provide in vivo evidence that CAV1 may be functioning as a 
repressor of metastasis in malignant melanoma. We first demonstrated that introduction of CAV1 
using retroviral strategy was sufficient to achieve high protein expression levels in B16F10 cells, 
and both CAV1 and CAV2 were correctly targeted to the plasma membrane. The over-expression 
of CAV1 resulted in an increase in cell proliferation in vitro, but did not affect primary tumor 
growth in vivo.  Conversely, CAV1 expression decreased migration and invasion in vitro, while 
suppressing the ability of these cells to metastasize in vivo.  These results translated to human 
cancer cell lines and melanoma tissue. Primary melanoma tissue samples and cell lines showed 
significant CAV1 expression in comparison to normal human melanocytes, while metastatic cell 
lines and tissue samples showed complete loss or a striking reduction in CAV1 levels.  Finally, 
we show that B16F10 cells expressing CAV1 displayed decreased expression of integrin β3 and 
reduced expression and activity of FAK and Src proteins following integrin activation.  Thus, 
here we demonstrate for the first time that CAV1 may be functioning to suppress metastasis in 
malignant melanoma.  
 The role of CAV1 in regulating critical aspects of melanomagenesis has not previously 
been addressed. Our results showing CAV1 expression in primary human melanoma tumors and 
cell lines versus its reduced expression in metastatic tissues and cell lines may indicate that 
CAV1 expression contributes to primary tumor growth, while its loss is a key factor in metastatic 
progression.  Thus, it appears evident that CAV1 has a biphasic expression pattern in melanoma, 
in which it is being upregulated in primary tumors compared to melanocytes and ultimately lost 
in melanoma metastasis.    
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Given that both our mouse and human tissue data indicate that CAV1 behaves as a “metastasis 
suppressor gene” in malignant melanoma, we next sought to examine possible mechanisms for 
this observed phenotype.  A large body of experimental in vivo and in vitro evidence has 
demonstrated that Extracellular Matrix (ECM)-cell interactions are critical to acquire the 
metastatic phenotype. Integrins are families of surface heterodimeric molecules that regulate 
adhesion of different ECM components such as collagen and fibronectin to the cell’s actin 
cytoskeleton, and these interactions occur at focal adhesions (FAs)(28). Multiple structural and 
signaling molecules have been shown to localize to focal adhesions, and FAK and Src seem to 
play key roles in regulating the dynamics of these structures in terms of signaling and protein-
protein interaction (35). Interestingly, CAV1 has been demonstrated to functionally interact with 
components of the FA complex. CAV1 has also been shown to localize to FAs and regulate the 
dynamics of these structures following integrin activation (26, 31). However, it seems that the 
function of CAV1 in regulating the Integrin/Src/FAK pathway is cell-type specific, behaving as a 
suppressor or an enhancer of this pathway activity depending on cell context (31, 36, 37).    
Because of these considerations, we investigated the role of CAV1 in regulating the activity and 
the expression of FAK and Src proteins following integrin activation in B16F10 cells. Our results, 
showing a significant reduction in the activities and expression of both Src and FAK in B16F10 
cells expressing CAV1, are consistent with their reduced motility in vitro and with their reduced 
metastatic potential in vivo.  Our results are in agreement with studies that show that reduction of 
activity and/or expression of FAK protein in melanoma cells suppresses their motility and their 
ability to form metastases in vivo (38) (39-41) (42). Additionally, CAV1 expression in B16F10 
cells resulted in a dramatic reduction in the expression of integrin β3 and integrin α5, two 
molecules often implicated in regulating the motility and metastatic ability of melanoma cells 
(32) (33) (43). In addition to alterations in Integrin/Src/FAK signaling, integrin engagement in 
these cells also affects proliferative and apoptotic pathways.  When plated on FN in the absence 
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of serum, B16F10 cells expressing CAV1 had reduced levels of Cyclin-D1 and of the 
antiapoptotic protein Bcl-2, an effect that is reversed when the cells were incubated with medium 
containing serum.  This suggests that CAV1 promotes proliferative and suppresses apoptotic 
pathways only in the presence of a proliferative stimulus, i.e. serum, a result supported by 
increased [3H]thymindine incorporation only in complete medium.   Uncoupling of signals 
regulating proliferation and migration have been observed before (44) (45), and may indicate a 
contextual effect of CAV1 on mechanisms regulating proliferation and migration. To our 
knowledge, this is the first study linking the ability of CAV1 to promote cell proliferation and 
suppress metastatic potential in melanoma with alterations in Integrin/Src/FAK signaling. 
 
In conclusion, we demonstrate that CAV1 expression promotes B16F10 melanoma cell 
proliferation while dramatically suppressing their ability to form metastases in vivo.  In human 
tissue, CAV1 expression is maintained in primary melanoma tumors but is reduced or lost in a 
large proportion of metastatic lesions.  Mechanistically, this phenotype was associated with the 
ability of CAV1 to decrease the expression of integrin β3 and to reduce the overall expression 
and activity of Src and FAK, two proteins critical in regulating FA dynamics. 
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FIGURE LEGENDS 
Figure 1. Absence of CAV1 expression in B16F0 (weakly metastatic) and B16F10 (highly 
metastatic) melanoma cell lines. (A) Immunoblotting of retrovirally transduced pBabe and 
pBabeCAV1 B16F10 and B16F0 cells for CAV1 and CAV2. S-100 immunoblot is shown as 
loading control. Note the absence of CAV1 expression in both pBabe transduced B16F0 and 
B16F10 cells. (B) Confocal Microscopy. Serial optical images (z sections) of pBabe and 
pBabeCAV1 B16F10 melanoma cells double immunostained with CAV1 and CAV2 antibodies 
demonstrate correct targeting of CAV1 to the plasma membrane. CAV2 extensively co-localizes 
with CAV1 in B16F10pBabeCAV1 cells (Scale Bar, 20µm). (C) Immunoblot analysis of 
cytoplasmatic (C) and membrane (M) fractions reveals that both CAV1 and CAV2 are enriched 
in the membrane fraction of B16F10pBabeCAV1 cells. Immunoblot for the membrane protein 
Flotillin-1 is also displayed. (D) Immunoblot analysis of Triton X-100 soluble (S) and insoluble 
(I) fractions reveals that CAV1 is enriched in the Triton X-100 insoluble fraction. Note that 
CAV1 expression renders CAV2 Triton X-100 insoluble in B16F10 cells. 
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Figure 2. CAV1 expression promotes proliferation of B16F10 melanoma cells in vitro.  (A) 
Growth Curves of pBabe and pBabeCAV1 B16F10 cells grown in 5% and 10% FBS (n=3, per 
group) showing CAV1 expression increases cell growth. (B) A [3H]-Thymidine incorporation 
assay showing increased proliferative rate of B16F10 cells expressing CAV1 (n=6, per group). 
(C) FACS analysis demonstrating increased % of B16F10pBabeCAV1 in the S/G2M phases of 
the cell cycle (n=4, per group). (D) Immmunoblot analysis showing increased CyclinD1 and 
CyclinA expression in B16F10pBabeCAV1 cells (top). Positivity for the proliferative marker 
Ki67 is also displayed (bottom). Results are reported as means ± SEM (* P<0.05; as determined 
by two-tailed Student’s t-test). 
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Figure 3. CAV1 expression decreases migration and invasion of B16F10 melanoma cells in 
vitro. Chemotaxis (A) and Chemoinvasion (B) were performed by seeding 5x104 pBabe and 
pBabeCAV1 B16F10 cells in the upper wells of matrigel coated (for chemoinvasion) or uncoated 
(for chemotaxis) transwell chambers in serum-free medium containing 0.1% BSA. Serum-free 
conditioned medium (48h) from cultures of NIH3T3 cells was used as chemoattractant in the 
lower wells. After 6h, the cells that had migrated to the underside of the membrane were washed 
with PBS, stained with crystal violet and counted.  Data represent the average of three 
independent experiments. Five fields per sample were counted. Results are reported as means ± 
SEM (*P<0.05; as determined by two-tailed Student’s t-test). 
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Figure 4. CAV1 expression dramatically reduces the metastatic potential of B16F10 
melanoma cells without affecting primary tumor growth. (A) Tumor Growth. Effect of CAV1 
expression on B16F10 tumor growth in vivo (n ≥7, per group).  (B, C) Experimental lung 
metastasis assay.  Effect of CAV1 expression on the metastatic ability of B16F10 cells 
represented as incidence (B) and number of visible metastases per lung (C) (n ≥ 18, per group). 
Note that CAV1 expression significantly reduces the ability of B16F10 melanoma cells to form 
lung metastasis in C57Bl/6 mice (**P=0.0014; as determined by a two tailed Fisher’s Exact 
Test). (D) Representative images of lung lobes dissected from mice IV injected with pBabe and 
pBabeCAV1 B16F10 cells. Results are reported as means ± SEM (*P<0.05; as determined by 
two-tailed Student’s t-test). 
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Figure 5. CAV1 expression is reduced in human metastatic melanoma cell lines and human 
tissue samples derived from metastatic lesions. (A) Immunoblot analysis showing CAV1 
expression in primary human melanoma cell lines (WM35,WM115) compared to a reduced or 
absent CAV1 expression in primary melanocytes (NHEM) and metastatic melanoma cell lines 
(SK-MEL-28, A-375, SK-MEL-5, WM-266-4). β-Tubulin is used as loading control. (B) 
Distribution of CAV1 immunoreactivity scores in primary melanoma and metastatic lesions 
(tissue microarray, 69 cases, 207 tissue cores) shows that primary tumors display significantly 
high immunoreactivity scores compared to metastatic lesions (P•0.0001; as determined by χ2 
test). (C) Representative CAV1 immunostaining in normal skin (left), primary melanoma 
(center), and metastasis tissue sections (right). Note the intense CAV1 staining in primary 
melanoma and in the basal cell layer of normal skin in contrast to reduced or absent CAV1 
staining in metastases (Scale Bar, 50µm). (D) Relative expression levels of CAV1 mRNA were 
determined in normal human skin and Stage III, and Stage IV metastatic lesions. CAV1 mRNA 
expression levels were normalized to RPL13a mRNA, and samples (closed circles) were grouped 
according to stage and averaged (solid lines). Note that CAV1 mRNA expression in Stage IV 
metastases is significantly reduced compared to CAV1 mRNA in Stage III and normal skin 
(*P<0.05 between groups; as determined by Tukey’s multiple comparisons test and two-tailed 
Student’s t-test).   
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Figure 6. CAV1 suppresses the Integrin/Src/FAK pathway following integrin engagement in 
B16F10 melanoma cells. (A) pBabe and pBabeCAV1-B16F10 melanoma cells were serum 
starved for 18h and were then re-plated on FN coated plates for 1h in serum free medium and 
either lysed (left) or pulsed for 10’ with 10% FBS containing medium and lysed (right). Western 
Blot analysis with antibodies directed against FAK, pFAK(Y397), Src, pSrc(Y418), and αV, β3, 
α6, α5, β1 integrins was performed. GAPDH was used as a loading control. Note that following 
integrin activation in SFM, both expression levels and activity of Src and FAK proteins and levels 
of β3 integrin are significantly reduced in B16F10pBabeCAV1 cells compared to B16F10pBabe 
cells.  Inhibition of Src and FAK activity is also maintained by CAV1 expression in B16F10 cells 
treated with serum (right). (B) Immunoblot analysis of pBabe and pBabeCAV1 B16F10 cells 
maintained in suspension demonstrates that CAV1 expression does not affect expression and 
activity of FAK and Src proteins. (C, Top) [3H]Thymidine incorporation assay of pBabe and 
pBabeCAV1 B16F10 cells plated on FN for 12h in SFM or 10% FBS (n ≥6, per group) shows 
that CAV1 promotes proliferation only in the presence of serum.  (C, Bottom) Immunoblot 
analysis of pBabe and pBabeCAV1 B16F10 cells plated on FN as in (A) showing CAV1 
expression reduces Bcl-2 and CyclinD1 in SFM while their expression is increased in FBS 
containing medium.   
 
 
